These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 39024257)

  • 1. Exploration of weekly variation in naloxone possession and carriage among people who use opioids in New York City before, during, and after the COVID-19 pandemic.
    Roth AM; Ward KM; Hensel DJ; Elliott L; Bennett AS
    PLoS One; 2024; 19(7):e0307151. PubMed ID: 39024257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial/ethnic disparities in opioid overdose prevention: comparison of the naloxone care cascade in White, Latinx, and Black people who use opioids in New York City.
    Khan MR; Hoff L; Elliott L; Scheidell JD; Pamplin JR; Townsend TN; Irvine NM; Bennett AS
    Harm Reduct J; 2023 Feb; 20(1):24. PubMed ID: 36841763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxone protection, social support, network characteristics, and overdose experiences among a cohort of people who use illicit opioids in New York City.
    Bennett AS; Scheidell J; Bowles JM; Khan M; Roth A; Hoff L; Marini C; Elliott L
    Harm Reduct J; 2022 Mar; 19(1):20. PubMed ID: 35246165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study.
    Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Christmass M; Dunlop A; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Treloar C; Dore GJ; Grebely J;
    Int J Drug Policy; 2021 Oct; 96():103421. PubMed ID: 34452808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary effectiveness of online opioid overdose and naloxone administration training and impact of naloxone possession on opioid use.
    Sisson ML; Azuero A; Chichester KR; Carpenter MJ; Businelle MS; Shelton RC; Cropsey KL
    Drug Alcohol Depend; 2023 Aug; 249():110815. PubMed ID: 37336007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naloxone distribution and possession following a large-scale naloxone programme.
    Madah-Amiri D; Gjersing L; Clausen T
    Addiction; 2019 Jan; 114(1):92-100. PubMed ID: 30129078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Fentanyl Test Strip Use, Perceived Overdose Risk, and Naloxone Possession among People Who Use Drugs.
    Tilhou AS; Zaborek J; Baltes A; Salisbury-Afshar E; Malicki J; Brown R
    Subst Use Misuse; 2024; 59(2):254-257. PubMed ID: 37807227
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluating disparities in prescribing of naloxone after emergency department treatment of opioid overdose.
    Weiner SG; Carroll AD; Brisbon NM; Rodriguez CP; Covahey C; Stringfellow EJ; DiGennaro C; Jalali MS; Wakeman SE
    J Subst Abuse Treat; 2022 Aug; 139():108785. PubMed ID: 35537918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlates of take-home naloxone kit possession among people who use drugs in British Columbia: A cross-sectional analysis.
    Moustaqim-Barrette A; Papamihali K; Crabtree A; Graham B; Karamouzian M; Buxton JA
    Drug Alcohol Depend; 2019 Dec; 205():107609. PubMed ID: 31654839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A qualitative study of repeat naloxone administrations during opioid overdose intervention by people who use opioids in New York City.
    Parkin S; Neale J; Brown C; Jones JD; Brandt L; Castillo F; Campbell ANC; Strang J; Comer SD
    Int J Drug Policy; 2021 Jan; 87():102968. PubMed ID: 33096365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with gaps in naloxone knowledge: evidence from a 2022 great plains survey.
    Cooper-Ohm S; Habecker P; Humeniuk R; Bevins RA
    Harm Reduct J; 2024 Feb; 21(1):37. PubMed ID: 38336722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gaps in naloxone ownership among people who inject drugs during the fentanyl wave of the opioid overdose epidemic in New York City, 2018.
    Rivera AV; Nolan ML; Paone D; Carrillo SA; Braunstein SL
    Subst Abus; 2022; 43(1):1172-1179. PubMed ID: 35617642
    [No Abstract]   [Full Text] [Related]  

  • 13. Personal experience and awareness of opioid overdose occurrence among peers and willingness to administer naloxone in South Africa: findings from a three-city pilot survey of homeless people who use drugs.
    Wilson M; Brumwell A; Stowe MJ; Shelly S; Scheibe A
    Harm Reduct J; 2022 Feb; 19(1):17. PubMed ID: 35148779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders.
    Abdelal R; Raja Banerjee A; Carlberg-Racich S; Darwaza N; Ito D; Shoaff J; Epstein J
    Harm Reduct J; 2022 May; 19(1):49. PubMed ID: 35596213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Awareness, Possession, and Use of Take-Home Naloxone Among Illicit Drug Users, Vancouver, British Columbia, 2014-2015.
    Nolan S; Buxton J; Dobrer S; Dong H; Hayashi K; Milloy MJ; Kerr T; Montaner J; Wood E
    Public Health Rep; 2017; 132(5):563-569. PubMed ID: 28750193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perception and Correlates of Opioid Overdose Risk Among Overdose Survivors Who Use Nonprescribed Opioids in San Francisco and Boston.
    Chang YG; McMahan VM; Marti XL; Pope E; Wolfe S; Majeski A; Reed G; Walley AY; Coffin PO
    Subst Use Addctn J; 2024 Oct; 45(4):559-567. PubMed ID: 38456483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The COVID-19 pandemic and the health of people who use illicit opioids in New York City, the first 12 months.
    Bennett AS; Townsend T; Elliott L
    Int J Drug Policy; 2022 Mar; 101():103554. PubMed ID: 34911010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes to opioid overdose deaths and community naloxone access among Black, Hispanic and White people from 2016 to 2021 with the onset of the COVID-19 pandemic: An interrupted time-series analysis in Massachusetts, USA.
    Zang X; Walley AY; Chatterjee A; Kimmel SD; Morgan JR; Murphy SM; Linas BP; Nolen S; Reilly B; Urquhart C; Schackman BR; Marshall BDL
    Addiction; 2023 Dec; 118(12):2413-2423. PubMed ID: 37640687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of patterns of opioid overdose and interventions delivered at a tertiary hospital emergency department: impact of COVID-19.
    Potaka KL; Freeman R; Soo D; Nguyen NA; Sim TF; Moullin JC
    BMC Emerg Med; 2022 Apr; 22(1):62. PubMed ID: 35397487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
    Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.